Laboratorio Emotest s.r.l.

COAGULATION

CYCLE 15 SAMPLE 10

Explanation of codes used in this report

R - Results removed due to reconstitution error
N - No result returned
C - Result corrected

Authorised by: Sally Picton, RIQAS Manager | Issue No: 1 | Issue Date: 18/10/2023

Randox Laboratories Limited
55 Diamond Road
CRUMLIN BT29 4QY
Tel: +44 (0)28 9445 4399
Fax: +44 (0)28 9445 4398
Email: mail@riqas.com

RIQAS

UKAS PROFICIENCY TESTING 0010

D-Dimer (Pilot), ng/ml FEU (2:1)

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	924	3170.299	41.6	54.27	668.81	225
Biomerieux VIDAS Exclusion II	66	27216.304	8.0	336.83	5741.59	62
Biomerieux Vidas/miniVidas/Vidas 3	66	27216.304	8.0	336.83	5741.59	61

▲ Your Result	27500.000	SDI	0.05
		RMSDI	Too Few
Mean for Comparison	27216.304	TS	120
		RMTS	Too Few
		%DEV	1.0
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	34.70%



Method	N	Mean	CV%	U_m
Siemens Innovance D-Dimer	285	3478.335	10.5	27.11
HemosIL D-Dimer HS 500	156	2745.327	6.2	16.94
Stago Sta Liatest D-DI/Plus	129	4747.101	9.5	49.52
Biomerieux VIDAS Exclusion II	66	27216.304	8.0	336.83
HemosIL D-Dimer	47	2891.511	46.0	242.64
HemosIL D-Dimer HS	46	2390.380	7.6	33.52
Roche Cobas D-DI 2	25	578.080	12.0	17.40
Roche Cobas D-DI2 citrated plasma	18	615.667	12.6	22.92
HemosIL D-Dimer 500	11	2725.455	6.2	64.03
Abbott Architect/Alinity Quantia D-Dimer	11	3018.858	4.0	45.67
ImproGen D-Dimer	10	378.970	7.0	10.49
Diagon D-Dimer	10	2438.000	11.4	109.67
Kinetic Latex Turbidimetry D-Dimer	7	491.429	5.2	12.02
Roche Cobas t511/t711 D-DI2	8	564.375	1.8	4.52
Siemens Immulite 2000 D-Dimer	8	6920.125	18.6	570.03
Siemens D-Dimer Plus	7	6911.143	5.9	191.11
Finecare D-Dimer	6	4021.667	21.3	436.68
Roche Integra D-DI 2	6	719.833	19.6	71.88
Mindray D-Dimer	6	2045.667	26.7	278.90
Roche Cobas h232 D-Dimer	5	6216.000	15.5	538.37
SNIBE Maglumi analyser	1	3360.000	0.0	0.00









RIQAS

UKAS PROFICIENCY TESTING 0010

Fibrinogen, mg/dl

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	2101	180.213	10.8	0.53	19.50	176
Siemens/Dade Thrombin	526	167.480	7.9	0.72	18.12	38
Sysmex CA 500/600 series	147	175.382	8.4	1.52	18.97	12

Your Result	167.000	SDI	-0.44
		RMSDI	Too Few
Mean for Comparison	175.382	TS	107
		RMTS	Too Few
		%DEV	-4.8
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	17.80%



Method	N	Mean	CV%	U_m
Siemens/Dade Thrombin	526	167.480	7.9	0.72
Stago Fibrinogen/ Liquid-Fib	400	196.578	5.4	0.65
HemosIL QFA (bovine thrombin)	250	175.567	9.9	1.37
HemosIL Fibrinogen C	223	184.850	8.6	1.32
Siemens/Dade Multifibren U	198	181.222	9.2	1.48
Sclavo Fibrinogen	36	187.336	10.1	3.95
HemosIL RecombiPlasTin 2G	31	140.179	11.2	3.53
Diagon Dia-FIB	27	152.507	6.2	2.27
Biolabo Bio-Fibri	27	189.967	11.4	5.19
Mindray/Longisland Fibrinogen	20	180.200	7.2	3.60
HemosIL PT-Fibrinogen HS Plus	22	183.273	10.1	4.93
Roche Cobas t511/t711 Fibrinogen	23	196.391	7.6	3.90
Human Fibrinogen	20	196.212	6.8	3.74
Helena Clauss Fibrinogen 100	18	199.239	5.5	3.25
Technoclone Fibrinogen	17	218.176	12.2	8.09
Bio-Ksel Fibrinogen	16	200.313	6.1	3.83
Labitec Fibrinogen	14	191.286	12.5	7.96
Roche Cobas t411 Fibrinogen	14	189.643	5.6	3.53
Yumizen G Fibrinogen	12	163.667	11.9	7.04
Siemens/Dade Innovin derived Fibrinogen	13	152.008	16.6	8.75
Tcoag TriniCLOT Fibrinogen	12	194.529	5.9	4.13









RIQAS

UKAS PROFICIENCY TESTING 0010

Antithrombin III activity, %

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	519	65.724	8.0	0.29	7.20	43
Siemens/Dade Berichrom ATIII	105	67.065	6.7	0.55	7.34	11
Sysmex CA 500/600 series	8	67.313	6.0	1.78	7.37	1

Your Result	68.000	SDI	0.09
		RMSDI	Too Few
Mean for Comparison	67.313	TS	120
		RMTS	Too Few
		%DEV	1.0
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	21.90%



Method	N	Mean	CV%	U_m
HemosIL Liquid Antithrombin	168	62.011	6.1	0.36
Siemens/Dade Berichrom ATIII	105	67.065	6.7	0.55
Siemens Innovance Antithrombin III	89	68.258	5.3	0.48
STAChrom ATIII	70	71.954	6.4	0.69
Sclavo ATIII	21	65.290	5.5	0.99
Roche Chromogenic Thrombin	9	62.967	3.9	1.03
Siemens/Dade Antithrombin III	10	69.645	7.2	1.98
Roche Antithrombin	10	65.340	6.9	1.79
HaemoDiagnostics Antithrombin III (Fxa)	7	63.154	7.7	2.29
HemosIL Lyophilised Antithrombin	5	63.520	17.0	6.03
Chromogenix Substrate	4	62.350	5.6	2.17
Tehnologia Standart Antithrombin III	4	60.025	7.9	2.97
Helena Chrom-Z	3	65.133	24.3	11.42
Biodevice ATIII	1	52.900	0.0	0.00
Diagon ATIII	2	74.500	2.8	1.87
Renam ATIII	2	62.750	10.7	5.94









RIQAS

UKAS PROFICIENCY TESTING 0010

aPTT as a ratio, RATIO

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	858	2.031	16.1	0.01	0.23	77
Siemens/Dade Actin FS	161	2.223	9.7	0.02	0.25	15
Sysmex CA 500/600 series	48	2.020	7.8	0.03	0.23	7

▲ Your Result	1.910	SDI	-0.49
		RMSDI	Too Few
Mean for Comparison	2.020	TS	111
		RMTS	Too Few
		%DEV	-5.4
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	21.90%



Method	N	Mean	CV%	U_m
Siemens/Dade Actin FS	161	2.223	9.7	0.02
HemosIL Synthasil	147	2.178	10.7	0.02
HemosIL APTT-SP liquid	98	1.591	5.1	0.01
Siemens/Dade Actin FSL	86	1.815	7.2	0.02
Stago CK Prest	64	2.019	5.9	0.02
Siemens/Dade Pathromtin SL	51	2.951	13.0	0.07
Stago PTT Automate	48	1.912	7.7	0.03
Sclavo APTT-S	19	2.738	10.9	0.09
Stago Cephascreen	15	1.979	9.6	0.06
Stago aPTT	16	1.926	10.1	0.06
Biolabo Bio-CK APTT	13	1.942	4.2	0.03
Helena aPTT Si L Minus	14	2.545	17.7	0.15
Human Hemostat APTT	11	1.995	5.0	0.04
Labitec aPTT	11	1.922	12.1	0.09
Erba Actime APTT	10	2.157	22.3	0.19
Bio-Ksel System APTTs	8	1.531	8.5	0.06
Tcoag TriniCLOT aPTT S	9	2.369	9.0	0.09
MTI Diagnostics APTT	6	2.024	4.7	0.05
Diagon Dia-PTT Lyophilised	5	1.918	6.7	0.07
Media IVD aPTT	5	1.627	21.2	0.19
Yumizen G APTT Liq	4	1.900	7.9	0.09









RIQAS

UKAS PROFICIENCY TESTING 0010

aPTT in seconds, s

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	3146	59.204	17.8	0.23	6.62	281
Siemens/Dade Actin FS	521	54.755	9.6	0.29	6.12	32
Sysmex CA 500/600 series	208	51.199	7.4	0.33	5.72	14

▲ Your Result	46.800	SDI	-0.77
		RMSDI	Too Few
Mean for Comparison	51.199	TS	91
		RMTS	Too Few
		%DEV	-8.6
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	21.90%



Method	N	Mean	CV%	U_m
Siemens/Dade Actin FS	521	54.755	9.6	0.29
Stago CK Prest	387	61.605	7.5	0.29
HemosIL Synthasil	400	66.137	14.4	0.59
Siemens/Dade Actin FSL	330	49.154	7.7	0.26
Siemens/Dade Pathromtin SL	274	91.780	12.6	0.87
HemosIL APTT-SP liquid	266	46.742	5.6	0.20
Stago PTT Automate	155	64.258	5.7	0.37
Stago aPTT	84	63.584	8.2	0.71
Stago Cephascreen	66	62.080	7.9	0.76
Human Hemostat APTT	52	57.344	12.7	1.26
Sclavo APTT-S	35	78.174	8.6	1.42
Beijing Succeeder aPTT	35	60.311	6.0	0.76
Biolabo Bio-CK APTT	31	58.868	8.1	1.07
Helena aPTT Si L Minus	30	72.103	17.2	2.83
Mindray/Longisland APTT	29	51.860	15.2	1.83
Roche Cobas APTT	30	74.033	13.8	2.33
Diagon Dia-PTT Liquid	25	55.700	5.5	0.76
Siemens/Dade Actin	25	52.783	8.5	1.12
Cobas aPTT MedS	23	83.290	6.7	1.46
Labitec aPTT	25	57.988	10.0	1.45
Bio-Ksel System APTTs	24	51.442	7.4	0.98









RIQAS

UKAS PROFICIENCY TESTING 0010

PT as an INR, INR

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	3059	1.531	27.1	0.01	0.17	200
Siemens/Dade Thromborel S	721	1.237	6.6	0.00	0.14	59
Sysmex CA 500/600 series	221	1.211	5.4	0.01	0.14	21

▲ Your Result	1.190	SDI	-0.16
		RMSDI	Too Few
Mean for Comparison	1.211	TS	120
		RMTS	Too Few
		%DEV	-1.8
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	21.90%



Method	N	Mean	CV%	U_m
Siemens/Dade Thromborel S	721	1.237	6.6	0.00
HemosIL RecombiPlasTin 2G	583	1.154	5.0	0.00
Stago STA-NeoPTimal	446	1.980	8.6	0.01
Siemens/Dade Innovin	435	2.180	10.8	0.01
Stago STA Neoplastine CI Plus	148	1.475	12.9	0.02
Human Thromboplastin	45	2.062	22.4	0.09
HemosIL PT-Fibrinogen HS Plus	41	1.500	6.0	0.02
Roche Cobas PT Screen	37	1.413	4.3	0.01
Beijing Succeeder PT	36	1.246	5.7	0.01
Sclavo PT	36	1.454	8.6	0.03
Stago Neoplastine R	28	1.169	6.1	0.02
Mindray/Longisland PT	27	1.576	11.1	0.04
Diagon, Dia-PT	24	1.438	20.3	0.07
Helena Thromboplastin L	25	1.701	18.8	0.08
HemosIL ReadiPlasTin	23	1.201	6.8	0.02
Roche Cobas PT Rec	22	2.986	6.8	0.05
Biolabo Bio-TP (Low ISI)	22	1.819	8.1	0.04
Bio-Ksel PT Plus	17	1.125	4.4	0.02
Labitec PT	14	1.502	8.0	0.04
Tcoag TriniCLOT PT Excel S	16	3.325	16.0	0.17
Biolabo Bio-TP	11	1.792	23.9	0.16









RIQAS

UKAS PROFICIENCY TESTING 0010

PT activity, %

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	1446	57.111	35.0	0.66	7.60	44
Siemens/Dade Thromborel S	302	68.175	11.0	0.54	9.08	24
Sysmex CA 500/600 series	94	68.551	9.4	0.83	9.13	12

▲ Your Result	65.300	SDI	-0.36
		RMSDI	Too Few
Mean for Comparison	68.551	TS	116
		RMTS	Too Few
		%DEV	-4.7
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	21.90%



Method	N	Mean	CV%	U_m
Siemens/Dade Thromborel S	302	68.175	11.0	0.54
HemosIL RecombiPlasTin 2G	266	80.225	6.8	0.42
Stago STA-NeoPTimal	259	39.901	9.1	0.28
Siemens/Dade Innovin	106	27.143	11.9	0.39
HemosIL PT-Fibrinogen HS Plus	38	52.652	11.0	1.17
Stago STA Neoplastine CI Plus	38	52.871	19.7	2.11
Beijing Succeeder PT	25	78.847	7.4	1.45
Human Thromboplastin	17	25.545	26.9	2.08
Sclavo PT	24	62.875	10.4	1.67
Helena Thromboplastin L	20	49.939	18.5	2.58
Mindray/Longisland PT	20	55.200	22.4	3.46
Biolabo Bio-TP (Low ISI)	17	45.553	6.3	0.87
Stago Neoplastine R	19	73.263	8.3	1.74
Labitec PT	14	53.416	20.6	3.67
Roche Cobas PT Screen	11	65.536	3.5	0.87
Diagon, Dia-PT	10	54.160	8.4	1.80
Roche Cobas PT Rec	12	20.017	9.3	0.67
Tcoag TriniCLOT PT Excel S	11	23.059	21.9	1.91
Biolabo Bio-TP	8	30.150	19.5	2.60
Erba Protime PT	11	61.616	18.5	4.30
MTI Diagnostics Prothrombin Time	10	30.063	28.8	3.42









RIQAS

UKAS PROFICIENCY TESTING 0010

PT in seconds, s

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	3140	17.983	27.6	0.11	1.40	164
Siemens/Dade Thromborel S	710	14.132	5.8	0.04	1.10	54
Sysmex CA 500/600 series	223	13.615	5.3	0.06	1.06	21

▲ Your Result	14.500	SDI	0.84
		RMSDI	Too Few
Mean for Comparison	13.615	TS	79
		RMTS	Too Few
		%DEV	6.5
		RM%DEV	Too Few

Acceptable limits derived from Biological Variation	N/A
Acceptable limits of performance for RIQAS	12.80%



Method	N	Mean	CV%	U_m
Siemens/Dade Thromborel S	710	14.132	5.8	0.04
HemosIL RecombiPlasTin 2G	579	13.046	4.2	0.03
Siemens/Dade Innovin	454	22.005	10.3	0.13
Stago STA-NeoPTimal	441	25.131	7.3	0.11
Stago STA Neoplastine CI Plus	170	18.443	14.0	0.25
Human Thromboplastin	49	23.577	18.4	0.78
HemosIL PT-Fibrinogen HS Plus	41	20.590	4.1	0.17
Roche Cobas PT Screen	35	14.716	3.4	0.11
Beijing Succeeder PT	34	15.951	6.2	0.21
Helena Thromboplastin L	29	20.261	13.4	0.63
Sclavo PT	28	18.486	8.0	0.35
Mindray/Longisland PT	26	19.330	10.2	0.48
Diagon, Dia-PT	23	16.481	12.4	0.53
Biolabo Bio-TP	22	23.216	27.6	1.71
Stago Neoplastine R	23	15.800	5.6	0.23
HemosIL ReadiPlasTin	22	13.195	3.4	0.12
Roche Cobas PT Rec	22	28.355	7.4	0.56
Biolabo Bio-TP (Low ISI)	19	23.589	5.3	0.36
Labitec PT	20	18.431	13.0	0.67
Tcoag TriniCLOT PT Excel S	18	32.297	15.0	1.43
Erba Protime PT	15	17.907	9.5	0.55



TDPA = 12.8%







RIQAS

UKAS PROFICIENCY TESTING 0010

Analyte	Mean for Comparison	Your Result	SDI	RMSDI	%DEV	RM%DEV	TS	RMTS	Performance
D-Dimer (Pilot)	27216.304	27500.000	0.05	Too Few	1.0	Too Few	120	Too Few	
Fibrinogen	175.382	167.000	-0.44	Too Few	-4.8	Too Few	107	Too Few	
Antithrombin III activity	67.313	68.000	0.09	Too Few	1.0	Too Few	120	Too Few	
aPTT as a ratio	2.020	1.910	-0.49	Too Few	-5.4	Too Few	111	Too Few	
aPTT in seconds	51.199	46.800	-0.77	Too Few	-8.6	Too Few	91	Too Few	
PT as an INR	1.211	1.190	-0.16	Too Few	-1.8	Too Few	120	Too Few	
PT activity	68.551	65.300	-0.36	Too Few	-4.7	Too Few	116	Too Few	
PT in seconds	13.615	14.500	0.84	Too Few	6.5	Too Few	79	Too Few	

ORMSDI N/A **ORM%DEV N/A** **ORMTS N/A**

END OF REPORT

RIQAS

UKAS PROFICIENCY TESTING 0010